Biopharma SHAKTI: ₹10,000 Crore Initiative to Build India as Global Biopharma Manufacturing Hub

Union Budget 2026-27 launches Biopharma SHAKTI as comprehensive initiative with ₹10,000 crore investment to transform India into global biopharma manufacturing hub. The programme aims to build robust ecosystem for domestic production of biologics and biosimilars, high-value pharmaceutical intermediates, and advanced therapeutic products. Biopharma SHAKTI addresses critical gaps in biopharmaceutical manufacturing infrastructure, research and development capabilities, and technology transfer mechanisms. The initiative will support establishment of state-of-the-art biomanufacturing facilities, fermentation infrastructure, purification systems, and quality control laboratories meeting international regulatory standards including US FDA, EMA and WHO guidelines. Focus areas include monoclonal antibodies, recombinant proteins, vaccines, cell and gene therapies, and biosimilar development. The programme provides comprehensive support including capital subsidies for plant and equipment, R&D grants for product development, technology acquisition assistance, regulatory compliance support, and skilled manpower development through specialized training programs. Biopharma SHAKTI complements existing PLI scheme for pharmaceuticals and aims to reduce India's dependence on imported biologics while creating high-value manufacturing jobs and strengthening India's position in global biopharmaceutical value chains.